Medicare could sharply curtail who can get the new Alzheimer’s drug aducanumab (Aduhelm), which carries a price tag of $56,000 a year, to limit its financial hit. (Wall Street Journal)
Meanwhile, the watchdog group ICER placed aducanumab’s cost-effectiveness at $2,950 to $8,360 a year.
And Alzheimer’s experts — including ones who strongly supported the drug’s FDA approval — said aducanumab should be given to a much narrower group of Alzheimer’s patients than what the label calls for. (New York Times)
Black Americans with multiple sclerosis (MS) had a greater burden of disease than white Americans with MS, even after adjusting for socioeconomic status. (Neurology)
Fictional TV characters often recover quickly from severe traumatic brain injury (TBI) and do not experience many physical or psychological consequences, an analysis of 26 episodes of “The Punisher” showed. (Lancet Neurology)
Serum glial fibrillar acidic protein (GFAP), a marker of astrogliosis, distinguished frontotemporal lobar degeneration (FTLD) from primary psychiatric disorders and tracked FTLD progression. (Journal of Neurology, Neurosurgery & Psychiatry)
Postoperative care after deep brain stimulation surgery for Parkinson’s disease may be successfully managed at home, a randomized clinical trial found. (JAMA Neurology)
Cognitive impairment assessments in early old age might not be useful for dementia prediction, an analysis of the Whitehall II cohort suggested. (Lancet Healthy Longevity)
The road to aducanumab’s approval may have included behind-the-scenes meetings that started in 2019 between drug maker Biogen and a top FDA neuroscience official as part of a secret campaign called Project Onyx, according to a STAT investigation.
Life with a short-sleep gene: “If you paid me a million dollars to sleep eight hours tonight, I couldn’t.” (CNN)